



TasP

Antiretroviral Treatment as Prevention - ANRS 12249  
(Ukuphila kwami, ukuphila kwethu (my health for our health))



00317477

Ukuphila kwami, ukuphila kwethu

Africa Centre TasP Trial

## Serious Adverse Event Reporting

### ANRS 12249 Initial SAE Notification

SAE-AI

Completed forms must be sent to  
ANRS within 48 hrs.  
Email: [pharmacovigilance@anrs.fr](mailto:pharmacovigilance@anrs.fr)  
Fax: +33 153 946 002

SAE No.

SAE Visit Date

20151105

Initial Notification Date

20151106

Notification time

0845

#### 1. Patient details

TasP ID

51465

Name

S.M.D.

Sex

Male

☒ Female

Date of birth

19590103

Enrolment date

20150422

#### 2. Measurements

Height

000 Cms

Last known: Weight

52.7

Kgs

Weight Date

20151105

CD4 count

608

CD4 Date

20150423

Viral Load

<40

Viral Load Date

20150819

#### 3. By which criteria is this adverse event considered to be "Serious"?

Tick all that apply

- ☐ Resulted in death → Date of death Probable cause
- ☐ Life threatening (i.e. at risk of death at time of event)
- ☒ Caused or prolonged hospitalisation (not elective hospitalisation for a pre-existing condition)
- ☐ Persistent or significant disability / incapacity
- ☐ Congenital abnormality / birth defect
- ☐ Grade 4 clinical and biological events
- ☐ Other serious, medically-important condition → Specify

#### 4. Details of SAE

Enter each adverse event (e.g. symptom, sign, syndrome or diagnosis) on a separate line

Event Name

Date investigator  
became aware

Date of onset of SAE

1. Infection/Sepsis 20150105 20151029

2.

3.

4.

5.

#### 5. Description of SAE

Include details of body site, relevant laboratory tests, treatments received and relevant medical history.

Attach copies of any relevant hospital records, laboratory test results etc.

The patient attended clinic on 5/11/15 with a week's history of acute confusion, headache, urinary frequency + chronic diarrhoea. She was heavily diarrhoeic in the clinic.

On examination HR 128, RR 28, Chest clear, bilateral flank pain. No suprapubic pain + no peritonism. Pupils equal + reactive. Objectively no photophobia.

Urine dp: 3+ blood, 1+ ketones. She was referred to Hlabisa hospital via ambulance on the same day with ?pyelonephritis.

## 6. Medications

List all drugs taken (or prescribed) before occurrence of SAE

Generic Name	Daily dose	Route of administration	Indication	Date started	Date stopped	Causality assessment	Expected reaction? (BNF/SPC)	Action taken
1. Atripla	T	PO	HIV	20150422		<input checked="" type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input checked="" type="radio"/> Yes <input type="radio"/> No	<input checked="" type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
2. Isoniazid	300mg	PO	TB prophylaxis	20150422	20150919	<input checked="" type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input checked="" type="radio"/> Yes <input type="radio"/> No	<input checked="" type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
3. Pyridoxine	25mg	PO	Peripheral Neuropathy	20150422		<input checked="" type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input checked="" type="radio"/> Yes <input type="radio"/> No	<input checked="" type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
4. Hydrochlorothiazide	12.5mg	PO	Hypertension	20150819		<input checked="" type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input checked="" type="radio"/> Yes <input type="radio"/> No	<input checked="" type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
5. Atenolol	5mg	PO	Hypertension	20150819		<input checked="" type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input checked="" type="radio"/> Yes <input type="radio"/> No	<input checked="" type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
6.						<input type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop

## 7. Other causes of SAE, if unrelated to drugs mentioned in Section 6 above

7a. According to the physician, is this SAE likely to be related to participation in the research?

Yes ☐ No ☒

7b. According to the physician, is this SAE related to any causes other than the research?

This includes the patient's medical history

Yes ☒ No ☐  
Describe

Patient is immunocompromised. At risk of infection

## 8. SAE Outcome

Died

Unknown to date

☒ Ongoing

Improved

Recovered

→ A complementary SAE notification must be submitted within 8 days

→ Date of recovery

Recovered without sequelae

or

Recovered with sequelae

→ Describe

## Physician reporting SAE

Name MEANIE HILL

Signature [Signature]

Date form completed 20151106